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Abstract 19 
Sepsis is one of the most prevalent diseases in the world. The development of cardiac 20 
dysfunction in sepsis results in an increase of mortality. It is known that Bruton’s tyrosine 21 
kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 inflammasome activation, 22 
two key components in the pathophysiology of sepsis and sepsis-associated cardiac 23 
dysfunction. In this study we investigated whether pharmacological inhibition of BTK 24 
(ibrutinib 30 mg/kg and acalabrutinib 3 mg/kg) attenuates sepsis associated cardiac dysfunction 25 
in mice. 10-week old male C57BL/6 mice underwent CLP or sham surgery. One hour after 26 
surgery mice received either vehicle (5% DMSO + 30% cyclodextrin i.v.), ibrutinib (30 mg/kg 27 
i.v.) or acalabrutinib (3 mg/kg i.v.). Mice also received antibiotics and an analgesic at 6 and 18 28 
hours. After 24 hours, cardiac function was assessed by echocardiography in vivo. Cardiac 29 
tissue underwent western blot analysis to determine the activation of BTK, NLRP3 30 
inflammasome and NF-κB pathway. Serum analysis of 33 cytokines was conducted by a 31 
multiplex assay. When compared to sham-operated animals, mice subjected to CLP 32 
demonstrated a significant reduction in ejection fraction (EF), fractional shortening (FS) and 33 
fractional area change (FAC). The cardiac tissue from CLP mice showed significant increases 34 
of BTK, NF-kB, and NLRP3 inflammasome activation. CLP animals resulted in a significant 35 
increase of serum cytokines and chemokines (TNF-α, IL-6, IFN-g, KC, eotaxin-1, eotaxin-2, 36 
IL-10, IL-4, CXCL10 and CXCL11). Delayed administration of ibrutinib and acalabrutinib 37 
attenuated the decline of EF, FS and FAC caused by CLP and also reduced the activation of 38 
BTK, NF-kB and NLRP3 inflammasome. Both ibrutinib and acalabrutinib significantly 39 
 2 
suppressed the release of cytokines and chemokines. Our study revealed that delayed 40 
intravenous administration of ibrutinib or acalabrutinib attenuated the cardiac dysfunction 41 
associated with sepsis by inhibiting BTK, reducing NF-κB activation and the activation of the 42 
inflammasome. Cytokines associated with sepsis were significantly reduced by both BTK 43 
inhibitors. Acalabrutinib is found to be more potent than ibrutinib and could potentially prove 44 
to be a novel therapeutic in sepsis. Thus, the FDA-approved BTK inhibitors ibrutinib and 45 
acalabrutinib may be repurposed for the use in sepsis.  46 
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Introduction  47 
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an 48 
infection (1), which affects approximately 30 million people worldwide (2). In the UK, sepsis 49 
is the second leading cause of death with 36,000-64,000 patients dying each year (3) costing 50 
the NHS £2.5 billion annually (4). The development of cardiac dysfunction affects 40% of 51 
septic patients (5) and is associated with an increased mortality rate of 70-90% in comparison 52 
to 20% mortality in patients who do not present with cardiac dysfunction (6). However, the 53 
mechanisms that underlie this cardiac dysfunction are not well known. Evidence suggests that 54 
multiple factors contribute to the pathophysiology of the cardiac dysfunction associated with 55 
sepsis. These include the activation of NF-kB and NLRP3 leading to excessive formation of 56 
e.g. IL-1 and TNF-α (7,8). There are currently no drugs for the specific treatment of the cardiac 57 
dysfunction (or indeed the multiple organ dysfunction) associated with sepsis that specifically 58 
target NF-kB and the NLRP3 inflammasome.  59 
Bruton’s tyrosine kinase (BTK) plays a role in innate immunity and is a critical component in 60 
the development of B cells (9). The FDA has approved the use of the irreversible BTK 61 
inhibitors ibrutinib (first generation) in chronic lymphatic leukemia (CLL), mantle cell 62 
lymphoma (MCL), Waldenstrom macroglobulinemia (WM) and graft vs. host disease (10) and 63 
acalabrutinib (more selective, second generation) in MCL (11). Ibrutinib is also approved by 64 
the EMA for the treatment of CLL, MCL and WM (12), whereas acalabrutinib has received an 65 
orphan designation for CCL, MCL and lymphoplasmacytic lymphoma (13–15). During sepsis, 66 
bacterial LPS stimulates TLR4 and BTK is directly involved in the activation of this signaling 67 
pathway. Specifically, BTK binds to the TIR domain of TLR4 and its adaptor molecules (also 68 
found in other TLR’s) MyD88 and Mal, and results in downstream activation of NF-kB and 69 
the generation of proinflammatory cytokines (16). BTK also regulates the assembly and, hence, 70 
activation of the NLRP3 inflammasome by binding to the ASC component (17,18). Inhibition 71 
of BTK by BTK inhibitors reduces NF-kB activation and the formation of NF-kB-dependent 72 
cytokines in murine models of arthritis (19). 73 
Given the importance of TLRs and NLRP3 in the pathophysiology of sepsis, we hypothesized 74 
that BTK inhibitors, such as ibrutinib or acalabrutinib, may attenuate the cardiac dysfunction 75 
in a murine model of polymicrobial sepsis. Additionally, we set out to investigate the potential 76 
effects of BTK inhibition on a) the activation of NF-kB and NLRP3 in the heart, and b) the 77 
serum levels of key, pro- and anti-inflammatory cytokines and chemokines.  78 
Methods 79 
Ethical statement 80 
The Animal Welfare Ethics Review Board of Queen Mary University of London approved all 81 
experiments in accordance with the Home Office guidance on the operation of Animals 82 
(Scientific Procedure Act 1986) published by Her Majesty’s Stationary Office, and the Guide 83 
for the Care and Use of Laboratory Animals of the National Research Council. Work was 84 
conducted under U.K. home office project license number PC5F29685. All in vivo experiments 85 
are reported in accordance to ARRIVE guidelines (20). 86 
Animals 87 
This study was carried out on 40 ten-week-old male C57BL/6 mice (Charles River Laboratories 88 
UK Ltd., Kent, UK) weighing 25-30 g and kept under standard laboratory conditions. Six mice 89 
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were housed together (in each cage) with access to a chow diet and water ad libitum. They 90 
were subjected to a 12-hour light and dark cycle with a temperature maintained at 19-23oC.  91 
Drugs 92 
Ibrutinib and acalabrutinib were purchased from Selleck Chemicals. Stock solutions were made 93 
in DMSO 5% and cyclodextrin 30% (vehicle).  94 
Murine model of polymicrobial sepsis caused by cecum ligation and puncture (CLP)  95 
Mice were randomized to undergo either sham operation, CLP + vehicle (5% DMSO + 30% 96 
cyclodextrin), CLP + ibrutinib (30 mg/kg) or CLP + acalabrutinib (3 mg/kg). Before surgery, 97 
mice were injected with buprenorphine (0.05 mg/kg, i.p.). Mice were initially anesthetized by 98 
isoflurane (3 L/min) and oxygen (1 L/min) in an anesthetic chamber and maintained with 99 
isoflurane (2 L/min) and oxygen (1 L/min) via a face mask. Temperature was monitored via a 100 
rectal probe and kept at 37oC by a homeothermic mat. Veet® hair removal cream was used to 101 
remove the fur from the abdomen of the mouse and skin was then cleaned with 70% ethanol. 102 
The abdomen was opened with a 1.5 cm midline incision to expose the cecum. The cecum was 103 
fully ligated below the ileocecal valve, and a G-18 needle was used to puncture two holes in 104 
the top and bottom of the cecum. A small amount of feces was then squeezed out. The cecum 105 
was returned to the abdomen in its anatomical position and 5 ml/kg of saline was administered 106 
into the abdomen before its closure. Saline (10 ml/kg s.c.) was administered directly after 107 
surgery. One hour after CLP, vehicle (5% DMSO + 30% cyclodextrin), ibrutinib (30 mg/kg), 108 
or acalabrutinib (3 mg/kg) was administered intravenously. At 6 and 18 h after surgery, 109 
antibiotics (imipenem/cilastatin; 20 mg/kg dissolved in saline s.c.) and an analgesic 110 
(buprenorphine; 0.05 mg/kg i.p.) were administered. After 24 h, cardiac function was assessed 111 
by echocardiography in vivo. Mice that underwent sham surgery were not subjected to ligation 112 
or perforation of the cecum but were otherwise treated the same way, 1 h after surgery sham 113 
animals were treated with vehicle (5% DMSO + 30% cyclodextrin).  114 
Renal dysfunction analysis  115 
Renal dysfunction was analysed in all mice. The mice were anaesthetised with isoflurane (3 116 
L/min) and oxygen (1 L/min) before being sacrificed. Cardiac puncture was performed with a 117 
G25 needle and non-heparinized syringes to obtain approximately 0.7 ml of blood. The blood 118 
was immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). The 119 
heart and lungs were then removed. The blood samples were centrifuged for 3 min at 9000 120 
RPM to separate the serum, where 100 µL of serum was pipetted into an aliquot and snap 121 
frozen in liquid nitrogen and stored at -80oC for further analysis. The serum was then sent to 122 
an independent veterinary testing laboratory (MRC Harwell Institute, Oxford, UK) to blindly 123 
quantify serum urea and creatinine known markers of renal dysfunction. 124 
Echocardiography 125 
At 24 h after CLP, cardiac function was assessed with a Vevo 3100 imaging system 126 
(VisualSonics, Toronto, Ontario, Canada). Mice were fully sedated in an anesthetic chamber 127 
with isoflurane (3 L/min) and oxygen (1 L/min) and were then transferred to the 128 
thermoregulatory platform in the supine position, where their paws were taped on to the EKG 129 
leads. Anesthetic was maintained throughout the entire procedure via a nosecone with 130 
isoflurane (0.5-2.0 L/min) and oxygen (1 L/min). The fur on the chest was removed by Veetâ 131 
hair removal cream and pre-warmed echo gel was placed onto the shaven chest. The heart was 132 
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then imaged with the MX550D imaging probe. To measure the left ventricle in B-mode the 133 
probe was placed along the long axis of the left ventricle, and directed towards the right of the 134 
mouse, here we measured percentage fractional area change (FAC %). The probe was then 135 
rotated 90o to visualize the short axis in the M-mode where the following parameters were 136 
measured: the percentage ejection fraction (EF %) and fractional shortening (FS %). 137 
Western blot analysis 138 
Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative 139 
western blotting analysis. The antibody used were:  1:1000 rabbit anti-Ser176/180-IKKα/β, 140 
1:1000 rabbit anti-total IKKα/β, 1:1000 mouse anti-Ser32/36-IkBa,  1:1000 mouse anti-total 141 
IkBa , 1:1000 rabbit anti-NF-kB, 1:1000 rabbit anti-total BTK, 1:1000 rabbit anti-Tyr1217 142 
PLCg, 1:1000 rabbit anti-total PLCg (from Cell Signaling), 1:1000 rabbit anti-Tyr223-BTK, 143 
1:5000 rabbit anti NLRP3 inflammasome (from Abcam), 1:1000 mouse anti-caspase 1 (p20) 144 
(from Adipogen). The apex of the heart was taken and homogenized in 1:10 of homogenization 145 
buffer at 4oC. Nuclear and cytosolic proteins were then extracted as previously described (21) 146 
and concentrations were quantified by bicinchoninic acid (BCA) protein assay (Thermo Fisher 147 
Scientific Rockford, IL). Proteins were separated by 8% sodium dodecyl sulphate (SDS)-148 
PAGE and transferred to polyvinyldenedifluoride membranes. Membranes were blocked in 149 
10% milk solution with TBS-Tween and then incubated with the primary antibody overnight 150 
at 4oC. The next day the secondary antibody was added for 30 min at room temperature and 151 
visualized using the ECL detection system. Tubulin and and histone 3 were used as loading 152 
control. The immunoreactive bands were analyzed by the Bio-Rad Image Lab SoftwareTM 6.0.1 153 
and results were normalized to the sham bands.   154 
Multiplex flow immunoassay 155 
The principle of multiplex flow immunoassay technology has been reviewed previously 156 
(22,23). Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex Pro 157 
Mouse Chemokine 33-plex panel assay (Bio-Rad, Kabelsketal, Germany). The cytokines IL-158 
1ß, -2, -4, -6, -10, -16, CCL1, -2, -3, -4, -5, -7, -11, -12, -17, -19, -20, -22, -24, -25, -27, IFN-159 
γ, TNF-α and the chemokines CX3CL1, CXCL1, -2, -5, -10, -11, -12, -13, -16 and the growth 160 
factor GM-CSF were measured according to the manufacturer’s instructions. The assays were 161 
performed in one batch, with samples randomly distributed. The lower detection limit was 3.2 162 
pg/ml for all the analytes. Data were collected and analyzed using a Bio-Plex® 200 instrument 163 
equipped with Bio-Plex Manager software (Bio-Rad). 164 
Statistical analysis 165 
All data in text and figures are expressed as mean ± standard error mean (SEM) of n 166 
observations. Measurements obtained from the intervention, control and sham were analyzed 167 
by one-way ANOVA followed by a Bonferroni’s post hoc test on GraphPad Prism 6.0 168 
(GraphPad Software, Inc., La Jolla, CA, USA). Correlations coefficients were determined by 169 
Pearson’s correlation with P values based on two-tailed tests. Differences were considered to 170 
be statistically significant when P < 0.05.   171 
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Results 172 
Ibrutinib or acalabrutinib attenuate the cardiac dysfunction caused by CLP-sepsis 173 
When compared to sham-operated animals, mice subjected to CLP for 24 h (Figure 1A) 174 
demonstrated a significant reduction in EF, FS and FAC (P < 0.0001; Figure 1B-E) indicating 175 
the development of systolic cardiac dysfunction. The observed reduction in EF also negatively 176 
correlated with the rise of the chemokines CXCL10 and CXCL11, both of which are well 177 
known biomarkers of left ventricular dysfunction (Figure 1F-I). When compared to CLP mice 178 
treated with vehicle (control), the administration of ibrutinib (30 mg/kg) or acalabrutinib (3 179 
mg/kg) at 1 h after CLP significantly attenuated the decline in EF, FS and FAC caused by CLP 180 
(P < 0.01; Figure 1 B-E). The rise in the serum levels of the chemokines CXCL10 and CXCL11 181 
caused by CLP were also significantly reduced by either ibrutinib or acalabrutinib (P < 0.05, 182 
Figure 1F-I). No significant differences were observed in any of the cardiac parameters or 183 
cytokines measured in CLP animals treated with either ibrutinib or acalabrutinib (P > 0.05; 184 
Figure 1 B-I). To gain a better insight into the mechanism by which the two BTK-inhibitors 185 
reduce the cardiac dysfunction associated with sepsis, we investigated the effects of ibrutinib 186 
and acalabrutinib on a) BTK-activation and signaling, b) NF-kB activation and c) NLRP3 187 
inflammasome assembly and activation (see below).  188 
Ibrutinib or acalabrutinib attenuate the renal dysfunction caused by CLP-sepsis 189 
Urea and creatinine were measured to study the effect of CLP (in the absence and presence of 190 
BTK inhibitors) on kidney function. When compared to sham, mice subjected to CLP and 191 
treated with vehicle had a significant increase of urea and creatinine, indicating kidney 192 
dysfunction (Figure 2, P < 0.0001). Administration of ibrutinib (30 mg/kg) or acalabrutinib (3 193 
mg/kg) to CLP mice significantly attenuated the rise in urea and creatinine when compared to 194 
CLP mice treated with vehicle (Figure 2, P < 0.01), without any significant difference between 195 
the two treatment. 196 
Cardiac BTK is activated in CLP mice and reduced by ibrutinib or acalabrutinib  197 
Using Western blot analysis, we investigated whether CLP-sepsis leads to an activation of BTK 198 
in the heart. The activation of BTK and the subsequent activation of BTK-signaling involves 199 
a) phosphorylation of BTK at Tyr223 and b) the phosphorylation of PLCg at Tyr1217 by 200 
phosphorylated (activated) BTK as the first step in the BTK-signaling cascade. When 201 
compared to sham operated mice, CLP mice treated with vehicle demonstrated significant 202 
increases in the phosphorylation of cardiac BTK at Tyr223 and the phosphorylation of PLCg at 203 
Tyr1217, indicating that BTK is activated in septic hearts (P < 0.0001, Figure 3A). 204 
Administration of ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) in CLP mice resulted in a 205 
significant decrease in the phosphorylation of cardiac BTK at Tyr223 and the phosphorylation 206 
of PLCg at Tyr1217 when compared to CLP mice treated with vehicle (P < 0.0001, Figure 3B) 207 
demonstrating that the doses of the two BTK inhibitors used in our study caused a significant 208 
inhibition of BTK-signaling in the heart. No significant differences were observed in the degree 209 
of phosphorylation of cardiac BTK at Tyr223 and the phosphorylation of PLCg at Tyr1217 in 210 
CLP-animals treated with either ibrutinib or acalabrutinib (P > 0.05, Figure 3A&B).   211 
Cardiac NF-kB activation in CLP mice is reduced by ibrutinib or acalabrutinib 212 
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To understand the signaling mechanism associated with the observed cardiac dysfunction, we 213 
investigated the effect of BTK inhibition on the activation of key signaling pathways of 214 
inflammation including pathways leading to the activation of NF-κB. When compared to sham 215 
operated mice, CLP mice treated with vehicle had significant increases in the phosphorylation 216 
of IKKa/b at Ser176/180, the phosphorylation of IkBa at Ser32/36 and the translocation of p65 to 217 
the nucleus (P < 0.001, Figure 4A-C). When compared with CLP mice treated with vehicle, 218 
treatment of CLP mice with ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) significantly 219 
attenuated the increases in cardiac phosphorylation of IKKα/β at Ser176/180 and IκBα at Ser32/36 220 
and the nuclear translocation of p65 (P < 0.0001, Figure 4A-C). No significant differences 221 
were observed in the degree of phosphorylation of IKKa/b at Ser176/180, the phosphorylation of 222 
IkBa at Ser32/36 and the translocation of p65 to the nucleus in CLP animals treated with either 223 
ibrutinib or acalabrutinib (P > 0.05, Figure 4A-C).   224 
Cardiac NLRP3 activation in CLP mice is reduced by ibrutinib or acalabrutinib 225 
We next assessed the potential involvement of NLRP3 in the cardiac dysfunction of CLP mice. 226 
When compared to sham operated mice, CLP-sepsis (vehicle-treatment) resulted in the 227 
increased expression of the NLRP3 inflammasome and cleavage of pro-caspase-1 to caspase-228 
1 in the heart and a rise in serum IL-1b (P < 0.0001, Figure 5A-C). When compared to CLP 229 
mice treated with vehicle, treatment of CLP mice with ibrutinib or acalabrutinib significantly 230 
inhibited the expression of NLRP3, cleavage of pro-caspase-1 to caspase-1 and the rise in IL-231 
1b (P < 0.01, Figure 5A-C), without any significant difference between the two drug 232 
treatments.  233 
Relationship between BTK activation and cardiac dysfunction in CLP-sepsis  234 
To address the question whether the degree of activation of BTK correlates with alterations in 235 
cardiac function, we correlated the degree of phosphorylation of BTK at Tyr223 (Figure 6A) 236 
and the phosphorylation of PLCg at Tyr1217 (Figure 6B) with EF. We found a highly significant 237 
negative correlation between the degree of BTK and PLCg activation and the decline in EF, 238 
strongly suggesting that BTK activation drives or precedes the cardiac dysfunction associated 239 
with sepsis. To address the question whether the degree of activation of BTK also correlates 240 
with alterations in the activation of NF-kB, we correlated the degree of phosphorylation of 241 
BTK at Tyr223 with the translocation of p65 (Figure 6C) and the phosphorylation of IKKa/b at 242 
Ser176/180 (Figure 6D). We found a highly significant positive correlation between the degree 243 
of BTK activation and the activation of NF-kB when measured as either the translocation of 244 
p65 (Figure 6C) and the phosphorylation of IKKa/b at Ser176/180 (Figure 6D). To address the 245 
question whether the degree of activation of BTK also correlates with alterations in the 246 
assembly and activation of the inflammasome, we correlated the degree of phosphorylation of 247 
BTK at Tyr223 with either NLRP3 assembly (Figure 6E) or the activation of caspase-1 (Figure 248 
6F). We found a highly significant positive correlation between the degree of BTK activation 249 
and the NLRP3 (Figure 6E) increased expression and the activation of caspase-1 (Figure 6F).  250 
Systemic inflammation in CLP mice is reduced by ibrutinib or acalabrutinib  251 
We also studied the effect of CLP (in the absence and presence of BTK inhibitors) on the 252 
systemic synthesis of pro-inflammatory cytokines, anti-inflammatory cytokines and pro-253 
inflammatory chemokines. When compared to sham operated mice, CLP (vehicle) resulted in 254 
a significant rise in the serum levels of a) the pro-inflammatory cytokines TNF-a, IFN-g, IL-255 
6; b) the anti-inflammatory cytokines IL-4 and IL-10, and c) the pro-inflammatory chemokines 256 
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KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24 (P < 0.05, Figure 7A-H). The sepsis-induced 257 
increase in these cytokines and chemokines was significantly attenuated by both BTK 258 
inhibitors, the only exception being IL-6, which was not significantly reduced by ibrutinib but 259 
a trend in reduction was observed. No significant differences were observed in the levels of 260 
cytokines or chemokines in CLP animals treated with either ibrutinib or acalabrutinib (P > 261 
0.05, Figure 7A-H).  262 
The data of all other cytokines/chemokines/growth factors that we measured in all groups are 263 
provided in Supplemental Figure S1.   264 
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Discussion 265 
We show here, for the first time, that administration of two structurally different BTK inhibitors 266 
(ibrutinib and acalabrutinib) both ameliorate the cardiac dysfunction (measured as decline in 267 
EF, FS or FAC by echocardiography) caused by CLP-sepsis. The observed decline in EF also 268 
was associated with a significant increase in the serum levels of two, well-known biomarkers 269 
of left ventricular dysfunction, namely CXCL10 and CXCL11 (24–26). Most notably, ibrutinib 270 
or acalabrutinib also attenuated the rises in CXCL10 and CXCL11 caused by CLP-sepsis. In 271 
addition, ibrutinib or acalabrutinib also reduced the renal dysfunction (measured as increase in 272 
serum urea or creatinine) caused by CLP-sepsis. Thus, both BTK inhibitors reduced the cardiac 273 
and renal dysfunction caused by sepsis.  274 
What, then, is the mechanism by which ibrutinib or acalabrutinib reduce the cardiac (renal) 275 
dysfunction caused by sepsis? Ibrutinib is a potent BTK inhibitor, but not very specific (as it 276 
also inhibits a multitude of other kinases), which is approved by the FDA and the EMA for the 277 
use in CLL, MCL and WM. Acalabrutinib is a potent, but highly specific BTK inhibitor: At a 278 
(relatively high) concentration of 1 µM, acalabrutinib strongly inhibited only the following 5 279 
kinases: BTK, Bmx, ErbB4, RIPK2 and TEC, while the same concentration of ibrutinib 280 
inhibited 35 kinases. It should be noted that the doses of acalabrutinib and ibrutinib that we 281 
used in our study in the mouse resulted in a similar, approximately 70%, inhibition of BTK 282 
activity in septic hearts. We, therefore, propose that inhibition of BTK activity explains the 283 
observed beneficial effects of ibrutinib or acalabrutinib in sepsis. The activation of BTK and 284 
the subsequent activation of BTK signaling involves a) phosphorylation of BTK at Tyr223 and 285 
b) the phosphorylation of PLCg at Tyr1217 by phosphorylated (activated) BTK as the first step 286 
in the BTK signaling cascade (27). We report here that sepsis results in significant increases in 287 
the phosphorylation of cardiac BTK at Tyr223 and the phosphorylation of PLCg at Tyr1217, 288 
indicating that BTK is activated in septic hearts. Most notably, the activation of BTK 289 
negatively correlated with EF indicating that activation of BTK is associated with the cardiac 290 
dysfunction in sepsis. Indeed, inhibition of BTK activity with ibrutinib or acalabrutinib in the 291 
heart of septic animals reduces the cardiac dysfunction in sepsis suggesting that activation of 292 
BTK plays a pivotal role in the pathophysiology of the cardiac dysfunction in sepsis.  293 
What are the mechanisms by which the activation of BTK (in the heart) leads to cardiac 294 
dysfunction in sepsis? There is good evidence that a) the activation of BTK precedes the 295 
activation of NF-kB (16), and b) the activation of NF-kB plays an important role in the cardiac 296 
dysfunction in sepsis (28,29). Specifically, inhibition of the activity of NF-kB attenuates the 297 
cardiac dysfunction in sepsis (30,31). We report here, for the first time, that a) activation of 298 
BTK is associated activation of NF-kB in septic hearts, and b) inhibition of BTK activity with 299 
ibrutinib or acalabrutinib reduces both the activation of NF-kB in septic hearts and the cardiac 300 
dysfunction caused by sepsis. Thus, we propose that inhibition of the activation of NF-kB 301 
contributes to the observed beneficial effects of the BTK inhibitors ibrutinib and acalabrutinib 302 
in sepsis. When challenging BTK KO-mice with LPS, Gabhann and colleagues observed 303 
reduced i) activation of NF-κB p65, ii) Akt phosphorylation and iii) M1 polarisation of 304 
macrophages (32). 305 
Activation of NF-kB drives the formation of a number of pro- and anti-inflammatory cytokines 306 
and chemokines. We report here that CLP-sepsis leads to a significant increase in the serum 307 
levels of the pro-inflammatory cytokines TNF-a, IL-6, IFN-g, anti-inflammatory cytokines IL-308 
10, IL-4 and the chemokines KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24, all of which 309 
importantly contribute to the local and systemic inflammation and organ injury associated with 310 
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sepsis (33). Most notably, we see the powerful pro-inflammatory cytokine TNF-a to be 311 
ameliorated by both BTK inhibitors. TNF-a has been implicated in murine models of sepsis 312 
and in humans with sepsis. TNF-a acts in an autocrine and paracrine manner leading to 313 
macrophage production and activation, resulting in the release of other proinflammatory 314 
cytokines such as IL-6 and IL-8 (34,35).  315 
Similarly, there is also good evidence that activation of BTK plays a crucial role in the 316 
assembly and activation of the NLRP3 inflammasome (17,36). The activation of the NLRP3 317 
inflammasome has been suggested to play a role in the cardiac dysfunction (37) and the 318 
pathophysiology of sepsis (38). Others have reported that inhibition of the assembly and 319 
activation of NLRP3 inflammasome protects against microbial sepsis (38). We report here for 320 
the first time that a) activation of BTK is associated with the activation of the NLRP3 321 
inflammasome in septic hearts, and b) inhibition of BTK activity with ibrutinib and 322 
acalabrutinib reduces both the assembly and subsequent activation of the NLRP3 323 
inflammasome in septic hearts (and the cardiac dysfunction caused by sepsis). Thus, we 324 
propose that inhibition of the activation of the NLRP3 inflammasome may also contribute to 325 
the observed beneficial effects of the BTK inhibitors ibrutinib and acalabrutinib in sepsis.  326 
Activation of the NLRP3 inflammasome drives the formation of IL-1b and IL-18, both of 327 
which play an important role in the systemic inflammation and/or organ dysfunction in sepsis 328 
(39). Specifically, inhibition of caspase-1 results in an inhibition of IL-18 and IL-1b secretion, 329 
which, in turn, attenuated the cardiac dysfunction caused by myocardial ischemia (40). The 330 
role of the inflammasome in the pathophysiology of sepsis, however, is still controversial: For 331 
example, survival was similar in wild-type and caspase-1/11 knockout mice with sepsis, while 332 
the neutralization of IL-1 and IL-18 reduced mortality in endotoxemia (39). Here we show that 333 
BTK inhibition results in reduced serum levels of IL-1b, and this was associated with an 334 
improvement of cardiac function. 335 
The evaluation of the efficacy of the BTK inhibitors used in our study depends on the 336 
assumption that the development of organ dysfunction (and specifically cardiac and renal 337 
dysfunction) correlates with outcome. There is good evidence that the occurrence of cardiac 338 
and/or renal dysfunction correlates positively with an increase in mortality in patients with 339 
sepsis (6). We have, however, not investigated the effects of BTK inhibition on survival in 340 
animals with sepsis due to ethical reasons. It would be useful to confirm whether inhibition of 341 
BTK activity does, indeed, improve survival in longer models of sepsis (rather than the very 342 
acute model employed here).  343 
In addition to inhibiting BTK, ibrutinib and acalabrutinib also strongly inhibit four other 344 
kinases. To ensure that inhibition of BTK, indeed, accounts for the inhibition of NF-kB and 345 
the inflammasome and ultimately the observed beneficial effects in sepsis, it would be useful 346 
to repeat our study in BTK knockout mice. Interestingly, of the kinases which are strongly 347 
inhibited by ibrutinib and acalabrutinib, expression of ErbB4 (rather than its activation) may 348 
play a role in the cardiac dysfunction and cognitive impairment associated with sepsis (41). In 349 
contrast, RIP2 kinase is unlikely to play a significant role in sepsis, as the CLP-induced septic 350 
peritonitis was similar in RIP2 knockout mice and their wild-type litter mates (42).  351 
Conclusions  352 
There are currently no specific treatments, which reduce the cardiac dysfunction or, indeed, 353 
mortality in sepsis. Our data shows for the first time that two commercially available BTK 354 
 11 
inhibitors, ibrutinib or acalabrutinib, attenuate the CLP-induced cardiac dysfunction through 355 
inhibition of the activation of BTK/NF-kB and/or the NLRP3 inflammasome, which in turn 356 
reduces the formation of a number of chemokines and cytokines including TNF-a. Notably, 357 
no significant qualitative or quantitative differences were found with two, chemically distinct 358 
BTK-inhibitors suggesting that the observed beneficial effects of both compounds in 359 
experimental sepsis are likely to be a drug class related effect. Thus, BTK inhibitors are FDA-360 
approved drugs that maybe repurposed for the use in sepsis, but also for other diseases 361 
associated with either local or systemic inflammation. 362 
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Legends to figures  529 
 530 
Figure 1: Ibrutinib or acalabrutinib attenuate the cardiac dysfunction caused by CLP-531 
sepsis 532 
Mice were randomly assigned to undergo CLP or sham surgery (n=10). One hour later, mice 533 
were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO 534 
+ 30% cyclodextrin i.v.). Cardiac function was assessed 24 h after CLP surgery (n = 10 per 535 
group). (A) Illustration of the timelines of the CLP model. (B) Representative M-mode 536 
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echocardiograms. (C) Ejection fraction (%). (D) Fractional shortening (%). (E) Fractional area 537 
change (%). (F) CXCL10 serum concentration (pg/ml). (G) CXCL11 serum concentration 538 
(pg/ml). (H) correlation of ejection fraction and CXCL10 serum concentration. (I) Correlation 539 
of ejection fraction and CXCL11 serum concentration. All data are expressed as mean ± SEM 540 
for n number of observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 541 
0.05 was considered to be statistically significant when compared to the control by one-way 542 
ANOVA followed by a Bonferroni’s post hoc test. Correlations coefficients were determined 543 
by Pearson’s correlation with P values based on two-tailed tests. 544 
 545 
Figure 2: Ibrutinib or acalabrutinib attenuate the renal dysfunction caused by CLP-546 
sepsis 547 
Mice were randomly assigned to undergo CLP or sham surgery (n=10). One hour later, mice 548 
were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO 549 
+ 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected for analyses (n = 10 550 
per group). (A) Serum urea (mmol/L). (B) Serum creatinine (µmol/L). All data are expressed 551 
as mean ± SEM for n number of observations. A value of ****P < 0.0001, ***P < 0.001, **P 552 
< 0.01, *P < 0.05 was considered to be statistically significant when compared to the control 553 




Figure 3: Cardiac BTK is activated in CLP mice and reduced by ibrutinib or 557 
acalabrutinib  558 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were 559 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 560 
30% cyclodextrin i.v.). At 24 h after CLP surgery, the activation of BTK in the heart was 561 
analyzed by western blot analysis (n=5 per group). Specifically, densitometric analysis of the 562 
bands is expressed as relative OD of (A) phosphorylation of BTK at Tyr223 corrected for the 563 
corresponding total BTK and normalized using the related sham band. (B) Phosphorylation of 564 
PLCg at Tyr1217 corrected for the corresponding total PLCg. All data are expressed as mean ± 565 
SEM for n number of observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01, *P 566 
< 0.05 was considered to be statistically significant when compared to the control by one-way 567 
ANOVA followed by a Bonferroni’s post hoc test.  568 
 569 
 570 
Figure 4: Cardiac NF-kB activation in CLP mice is reduced by ibrutinib or acalabrutinib 571 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were 572 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 573 
30% cyclodextrin i.v.). At 24 h cardiac tissue was collected and signaling was assessed (n = 10 574 
per group). Densitometric analysis of the bands is expressed as relative OD of (A) 575 
phosphorylation of IKKa/b at Ser176/180 corrected for the corresponding total IKKa/b and 576 
normalized using the related sham band. (B) Phosphorylation of IkBa at Ser32/36 corrected for 577 
the corresponding total IkBa and normalized using the related sham band. (C) NF-kB p65 in 578 
both nucleus and cytosol and expressed as a ratio, normalized using the sham related bands. 579 
All data are expressed as mean ± SEM for n number of observations. A value of ****P < 580 
0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant when 581 
compared to the control by one-way ANOVA followed by a Bonferroni’s post hoc test.  582 
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 583 
Figure 5: Cardiac NLRP3 activation in CLP mice is reduced by ibrutinib or acalabrutinib 584 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were 585 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 586 
30% cyclodextrin i.v.). At 24 h after CLP surgery, the assembly and activation of NLRP3 in 587 
the heart was analyzed by western blot analysis (n=5 per group). Specifically, densitometric 588 
analysis of the bands is expressed as relative OD of (A) NLRP3 activation, corrected against 589 
tubulin and normalized using the sham related bands. (B) Pro-caspase-1 against activated 590 
caspase-1 and normalized using the sham related bands. (C) IL-1b serum concentration 591 
analyzed by multiplex assay. All data are expressed as mean ± SEM for n number of 592 
observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 was considered 593 
to be statistically significant when compared to the control by one-way ANOVA followed by 594 
a Bonferroni’s post hoc test. 595 
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 596 
Figure 6: Relationship between BTK activation and cardiac dysfunction in CLP-sepsis 597 
 21 
Correlation data to show (A) ejection fraction (%) vs. phosphorylation of BTK at Tyr223. (B) 598 
ejection fraction (%) vs. of PLCg at Tyr1217. (C) Phosphorylation of BTK at Tyr223 vs. NF-kB 599 
p65. (D) Phosphorylation of BTK at Tyr223 vs. phosphorylation of IKKa/b atSer176/180. (E) 600 
Phosphorylation of BTK at Tyr223 vs. NLRP3. (F) Phosphorylation of BTK at Tyr223 vs. 601 
activated/pro-caspase-1. Data was analyzed by the Pearson correlation coefficient test to 602 
calculate the r value and a two tailed T-test for significance, a value of ****P < 0.0001, ***P 603 
< 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant.  604 
 605 
 606 
Figure 7: Systemic inflammation in CLP mice is reduced by ibrutinib or acalabrutinib 607 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were 608 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 609 
30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected, and the serum 610 
concentration of cytokines and chemokines were measured by a multiplex assay (n = 8 per 611 
group). (A) TNF-a serum concentration (pg/ml). (B) IL-6 serum concentration (pg/ml). (C) 612 
IFN-g serum concentration (pg/ml). (D) KC/CXCL1 serum concentration (pg/ml). (E) Eotaxin-613 
1/CCL11 serum concentration (pg/ml). (F) Eotaxin-2/CCL24 serum concentration (pg/ml). (G) 614 
IL-10 serum concentration (pg/ml). (H) IL-4 serum concentration (pg/ml). All data are 615 
expressed as mean ± SEM for n number of observations. Correlations coefficients were 616 
determined by Pearson’s correlation with P values based on two-tailed tests a value of ****P 617 





Supplementary figure 1: Systemic inflammation in CLP mice is reduced by ibrutinib or 621 
acalabrutinib 622 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were 623 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 624 
30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected, and the serum 625 
concentration of cytokines and chemokines were measured by a multiplex assay (n = 8 per 626 
group). All data are expressed as mean ± SEM for n number of observations. A value of ****P 627 
< 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant 628 
when compared to the control by one-way ANOVA followed by a Bonferroni’s post hoc test. 629 
A value of $$$$P < 0.0001, $$P < 0.01, was considered to be statistically significant when 630 
compared to the sham by one-way ANOVA followed by a Bonferroni’s post hoc test. 631 
